Folch's team of scientists improved eczema in children with probiotic therapy.

, commonly known as eczema, is a chronic inflammatory skin disease characterized by dry skin, repeated itching and rash. This annoying disease is common in children and is most common in age groups under 7 years of age, and is also associated with an increased risk of asthma, hay fever and food allergies. While existing therapies can help control symptoms, they are often expensive and require routine care, and generally reflect that the effect is not particularly good.many genetic and environmental factors can lead to eczema, and scientists are learning more about the role of the skin microbiome in it.In a new study published in Translational Medicine in the early hours of September 10, Beijing time, a team led by the National Institutes of Allergy and Infectious Diseases (NIAID), the national institute of infectious diseases, the nation's leading infectious disease specialist, found that an experimental treatment designed to alter the skin microbiome could safely reduce the severity of eczema, reduce steroid use, improve the quality of life of children over the age of 3, and improve the quality of life of children over the age of 3 for up to eight months after treatment stopped.. This experimental therapy contains the active skin symbiotic bacteria Roseomonas. Initially, they were isolated from healthy volunteers and grew under carefully controlled laboratory conditions. Over a four-month period of treatment, participants in clinical trials or their caregivers regularly applied this probiotic therapy to areas of the skin affected by eczema.. Dr Anthony S. Fauci, director of NIAID, said: "Eczema can cause itching, pain and distraction in children and can have a very significant impact on the whole family. Early findings have shown that R. mucosa therapy can help some children reduce eczema symptoms and the burden of daily care. In2016, NIAID researchers reported that R. mucous membranes isolated from the skin of healthy volunteers improved the results of eczema models in cells and mice.these preclinical findings, NIAID conducted Phase 1/2 clinical trials at the NIH Clinical Center to assess the safety and potential benefits of R. mucosal therapy in eczema patients. Interim results from 10 adults and 5 children between the ages of 9 and 14 reported in 2018 showed that the treatment was safe and could reduce the severity of eczema. Since then, the trial has recruited 15 more children, with participants in a total of 20 children with mild to severe eczema, aged between three and 16.. R. The treatment plan for the mucous membranes is twice a week for three months and once the next day for the fourth month. Children or their caregivers spray a solution of sugar and water containing live R. mucous membranes into the eczema skin area. In the first 15 children who participated in the study, the dose of living R. mucous membranes increased month by month. The last five children received the same dose of treatment within 4 months. The results showed that no serious adverse events occurred regardless of the drug-giving strategy used.study, most of the children in the study showed substantial improvements in skin and overall health after receiving R. mucosa therapy. Encouragingly, the treatment of bacteria is fixed on the skin and continues to play a beneficial role after treatment. These results support a larger study that further evaluates the safety and ability of this experimental treatment by comparing it with a placebo.. Seven out of 20 children improved the severity of eczema by more than 50 per cent after treatment. All treated skin areas have improved, including the inner elbow, inner knee, hand, torso and neck. The researchers also observed an increase in skin barrier function, i.e. the ability to seal moisture and resist allergens. In addition, most children need fewer corticosteroids to control their eczema, experience fewer itching symptoms, and report improved quality of life after treatment. These benefits persist after treatment and the therapeutic R. mucosa bacteria stay on the skin for up to 8 months.. The next step for NIAID researchers will be to learn more about how R. mucosa therapy improves eczema symptoms. They found that treated skin microbiota increased and levels of Staphylococcus austrophy, a bacteria known to exacerbate eczema symptoms, decreased.addition to the imbalance in the skin microbiome, eczema patients lack certain oils in their skin. By experimenting with cellular and animal models of eczema, NIAID researchers found that a specific set of lipids produced by R. mucosa strains isolated from healthy skin can induce skin repair processes and promote skin tissue renewal. Study participants had increased lipid levels on their skin after treatment with R. mucous membranes.the local application of rose monocytobacteria mucous membrane was associated with clinical improvement of 15 cases of children's endemic dermatitis. This improvement may be associated with lipid production by bacteria that affect the skin repair mediated by TNFR2 by affecting nicotine-like acetylcholine signals and whiplash recognition.researchers stress that further research is needed to clarify the rationale for R. mucosa therapy and to explore whether genetic or other factors may explain why some participants did not benefit from experimental therapy.paper link:
.